The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy.

Joon Ho Choi Ilhan LimByung Hyun ByunByung Il KimChang Woon ChoiHye Jin KangDong-Yeop ShinSang Moo Lim

Published in: PloS one (2022)

Higher SUVmax at pretreatment 18F-FDG PET/CT was associated with better relapse free survival and overall survival in DLBCL patients after consolidation therapy with 131I-rituximab. However, because this study has a small number of patients, a phase 3 study with a larger number of patients is needed for clinical application in the future.

Keyphrases

diffuse large b cell lymphoma
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
bone marrow
mesenchymal stem cells